Angiotensin-(1–7) Dose-Dependently Inhibits Atherosclerotic Lesion Formation and Enhances Plaque Stability by Targeting Vascular Cells
Authors:
- 1 August 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 33 (8) , 1978-1985
Abstract
Objective—: To test the hypothesis that chronic infusion of angiotensin-(1–7) [Ang-(1–7)] may dose-dependently inhibit atherosclerotic lesion formation by targeting vascular smooth muscle cells and a large dose of Ang-(1–7) may stabilize mature plaque by targeting macrophages. Approach and Results—: In vivo, the effects of Ang-(1–7) on atherogenesis and plaque stability were observed in ApoE −/− mice fed a high-fat diet and chronic angiotensin II infusion. In vitro, the effects of Ang-(1–7) on vascular smooth muscle cells’ proliferation and migration, and macrophage inflammatory cytokines were examined. Ang-(1–7) dose-dependently attenuated early atherosclerotic lesions and inhibited vascular smooth muscle cells’ proliferation and migration via suppressing extracellular regulated protein kinase/P38 mitogen-activated protein kinase and janus kinase/signal transducers and activators of transcription activities and enhancing smooth muscle 22α and angiotensin II type 2 receptor expression. Ang-(1–7) treatment resulted in high contents of collagen and vascular smooth muscle cells, and low contents of macrophages and lipids in carotid mature plaques. Ang-(1–7) lowered the expression levels of proinflammatory cytokines and activities of matrix metalloproteinases in mature plaques. Conclusions—: Ang-(1–7) treatment inhibits early atherosclerotic lesions and increases plaque stability in ApoE −/− mice, thus providing a novel and promising approach to the treatment of atherosclerosis.Keywords
This publication has 28 references indexed in Scilit:
- Angiotensin-Converting Enzyme 2 Deficiency in Whole Body or Bone Marrow–Derived Cells Increases Atherosclerosis in Low-Density Lipoprotein Receptor −/− MiceArteriosclerosis, Thrombosis, and Vascular Biology, 2011
- Different Effects of Angiotensin II and Angiotensin-(1-7) on Vascular Smooth Muscle Cell Proliferation and MigrationPLOS ONE, 2010
- Angiotensin-converting enzyme 2 attenuates atherosclerotic lesions by targeting vascular cellsProceedings of the National Academy of Sciences, 2010
- Macrophage Plasticity in Experimental AtherosclerosisPLOS ONE, 2010
- Targeting the Degradation of Angiotensin II With Recombinant Angiotensin-Converting Enzyme 2Hypertension, 2010
- Human Recombinant ACE2 Reduces the Progression of Diabetic NephropathyDiabetes, 2009
- Onset of Experimental Severe Cardiac Fibrosis Is Mediated by Overexpression of Angiotensin-Converting Enzyme 2Hypertension, 2009
- Role of Smooth Muscle Cells in the Initiation and Early Progression of AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Angiotensin-(1-7) Through Receptor Mas Mediates Endothelial Nitric Oxide Synthase Activation via Akt-Dependent PathwaysHypertension, 2007
- Angiotensin-(1–7) Acts as a Vasodepressor Agent Via Angiotensin II Type 2 Receptors in Conscious RatsHypertension, 2005